

# Novo Nordisk

seeks partners within

chronic inflammatory  
and autoimmune disorders



## Novo Nordisk is a focused healthcare company

We are headquartered in Denmark and have affiliates in 80 countries.

Novo Nordisk is a worldwide market leader in diabetes with

- A full portfolio of insulin analogs
- The broadest portfolio of insulin delivery systems and a leading position in the global injection device market.

Novo Nordisk has a leading position in

- Hemophilia with inhibitors
- Growth hormone disorders
- Hormone replacement therapy.

## Our partnering focus

Novo Nordisk is expanding into

- Chronic inflammatory and autoimmune disorders, an area with a significant unmet medical need.

We welcome protein and peptide opportunities at early discovery phase as well as clinical projects. We particularly focus on the following targets:

- Surface molecules on cells involved in immune regulation, particularly T cells, NK cells, dendritic cells and monocytes/macrophages
- Cytokines and chemokines.

We maintain our interest in new anti-inflammatory projects and products for type 1 and type 2 diabetes.

## Our pipeline

Our pipeline contains fully human and humanized monoclonal antibodies in the clinic and in pre-clinical development for the treatment of autoimmune diseases, three of which are first-in-class compounds.


Furthermore, we have established a worldwide network of expert advisors within psoriasis, rheumatoid arthritis, systemic lupus, inflammatory bowel disease, multiple sclerosis and diabetes.





## Proteins from molecule to market

- We are committed to novel immunotherapies that will significantly improve the lives of people with autoimmune and chronic inflammatory diseases
- We build on our expertise in immunology and world-class recombinant protein technology.



## What do we offer our partners?

Our history throughout more than 85 years tells us that creativity thrives in partnerships. And that one-size does not fit all. So, we actively engage in partnerships and are open to the full range of set-ups from in-licensing to sophisticated partnerships. There are three special reasons for choosing Novo Nordisk as your future partner - read much more at [www.novonordisk.com/science/partnering](http://www.novonordisk.com/science/partnering).

- Full, global value chain: Proteins from molecule to market
- Focus: Life-long dedication to patient care and our business
- Fairness: Decency is what counts.



## Contacts



Jørn Roland Müller, Corp. VP, e-mail: [jrom@novonordisk.com](mailto:jrom@novonordisk.com)



Dan Zekzer, Senior Sourcing Director, e-mail: [daze@novonordisk.com](mailto:daze@novonordisk.com)



Thomas Hanke, Sourcing Director, e-mail: [thnk@novonordisk.com](mailto:thnk@novonordisk.com)



Anand Gautam, Sourcing Director, e-mail: [agum@novonordisk.com](mailto:agum@novonordisk.com)



Diabetes  
Finn Benned Hansen, Corp. VP, e-mail: [fbh@novonordisk.com](mailto:fbh@novonordisk.com)